Journal
SOCIAL STUDIES OF SCIENCE
Volume 48, Issue 5, Pages 740-761Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0306312718801165
Keywords
genetic homogeneity; pharmacogenomics; population branding; population genetics; stratified medicine
Categories
Funding
- Academy of Finland [132554, 292408]
- COST-Action Citizen's Health Through Public-private Initiatives: Public Health, Market and Ethical Perspectives (CHIP ME) [IS1303]
- Academy of Finland (AKA) [292408, 132554, 292408, 132554] Funding Source: Academy of Finland (AKA)
Ask authors/readers for more resources
Since the sequencing of the human genome, as well as the completion of the first Human Genome Diversity Project, the benefits of studying one human population over another has been an ongoing debate relating to the replicability of findings in other populations. The leveraging of specific populations into research markets has made headlines in cases such as deCode in Iceland, Quebec Founder Population, and Generation Scotland. In such cases, researchers and policy makers have used the genetic and historical uniqueness of their populations to attract scientific, commercial and political interest. In this article, we explore how in countries with population isolates, such as Finland, the researchers balance considerations relating to the generalization and replicability of findings in small yet unique research populations to global biomedical research interests. This highlights challenges related to forms of competition associated with genetics research markets, as well as what counts as the right' population for genetic research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available